Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8514 | 1246 | 41.8 | 75% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
350 | 3 | COMPLEMENT//MANNOSE BINDING LECTIN//IMMUNOLOGY | 35656 |
1655 | 2 | BIOSIMILAR//FCRN//PROTEIN FORMULATION | 6878 |
8514 | 1 | PROTEIN FORMULATION//PROTEIN AGGREGATION//SUBVISIBLE PARTICLES | 1246 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PROTEIN FORMULATION | authKW | 2059492 | 13% | 51% | 164 |
2 | PROTEIN AGGREGATION | authKW | 754233 | 21% | 12% | 256 |
3 | SUBVISIBLE PARTICLES | authKW | 616003 | 2% | 93% | 27 |
4 | LATE STAGE PHARMACEUT DEV | address | 472102 | 3% | 57% | 34 |
5 | FORMULAT SCI | address | 423744 | 3% | 41% | 42 |
6 | MACROMOL VACCINE STABILIZAT | address | 374492 | 3% | 48% | 32 |
7 | BIOPHARMACEUTICALS CHARACTERIZATION | authKW | 251315 | 2% | 51% | 20 |
8 | PROT PHARMACEUT DEV | address | 243603 | 1% | 76% | 13 |
9 | JOURNAL OF PHARMACEUTICAL SCIENCES | journal | 242016 | 27% | 3% | 332 |
10 | PHARM PHARMACEUT TECHNOL BIOPHARMACEUT | address | 225185 | 3% | 26% | 36 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 12925 | 59% | 0% | 733 |
2 | Chemistry, Medicinal | 10911 | 28% | 0% | 348 |
3 | Chemistry, Multidisciplinary | 4056 | 38% | 0% | 469 |
4 | Biochemical Research Methods | 688 | 9% | 0% | 108 |
5 | Chemistry, Analytical | 511 | 10% | 0% | 125 |
6 | Biotechnology & Applied Microbiology | 353 | 9% | 0% | 106 |
7 | Medicine, Research & Experimental | 198 | 6% | 0% | 73 |
8 | Biochemistry & Molecular Biology | 171 | 14% | 0% | 177 |
9 | Biophysics | 136 | 5% | 0% | 61 |
10 | Chemistry, Physical | 21 | 6% | 0% | 78 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | LATE STAGE PHARMACEUT DEV | 472102 | 3% | 57% | 34 |
2 | FORMULAT SCI | 423744 | 3% | 41% | 42 |
3 | MACROMOL VACCINE STABILIZAT | 374492 | 3% | 48% | 32 |
4 | PROT PHARMACEUT DEV | 243603 | 1% | 76% | 13 |
5 | PHARM PHARMACEUT TECHNOL BIOPHARMACEUT | 225185 | 3% | 26% | 36 |
6 | FORMULAT ANALYT OURCES | 191386 | 1% | 46% | 17 |
7 | PHARMACEUT DEV SUPPLIES | 171522 | 1% | 50% | 14 |
8 | PHARMA TECH DEV BIOL EUROPE | 152680 | 1% | 69% | 9 |
9 | DRUG DELIVERY TECHNOL | 149723 | 3% | 15% | 41 |
10 | DRUG PROD DEV | 138517 | 2% | 27% | 21 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF PHARMACEUTICAL SCIENCES | 242016 | 27% | 3% | 332 |
2 | MABS | 45511 | 3% | 5% | 37 |
3 | PHARMACEUTICAL RESEARCH | 36384 | 9% | 1% | 109 |
4 | BIOPHARM INTERNATIONAL | 9156 | 1% | 3% | 14 |
5 | EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS | 8522 | 3% | 1% | 36 |
6 | JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY | 7402 | 0% | 5% | 6 |
7 | PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY | 7389 | 1% | 3% | 9 |
8 | MOLECULAR PHARMACEUTICS | 6504 | 2% | 1% | 29 |
9 | AAPS JOURNAL | 4223 | 1% | 1% | 14 |
10 | INTERNATIONAL JOURNAL OF PHARMACEUTICS | 3209 | 4% | 0% | 46 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PROTEIN FORMULATION | 2059492 | 13% | 51% | 164 | Search PROTEIN+FORMULATION | Search PROTEIN+FORMULATION |
2 | PROTEIN AGGREGATION | 754233 | 21% | 12% | 256 | Search PROTEIN+AGGREGATION | Search PROTEIN+AGGREGATION |
3 | SUBVISIBLE PARTICLES | 616003 | 2% | 93% | 27 | Search SUBVISIBLE+PARTICLES | Search SUBVISIBLE+PARTICLES |
4 | BIOPHARMACEUTICALS CHARACTERIZATION | 251315 | 2% | 51% | 20 | Search BIOPHARMACEUTICALS+CHARACTERIZATION | Search BIOPHARMACEUTICALS+CHARACTERIZATION |
5 | LIGHT OBSCURATION | 192108 | 1% | 56% | 14 | Search LIGHT+OBSCURATION | Search LIGHT+OBSCURATION |
6 | POLYSORBATE | 190710 | 2% | 32% | 24 | Search POLYSORBATE | Search POLYSORBATE |
7 | LIGHT SCATTERING DYNAMIC | 125480 | 1% | 39% | 13 | Search LIGHT+SCATTERING+DYNAMIC | Search LIGHT+SCATTERING+DYNAMIC |
8 | FORMULATION | 118497 | 8% | 5% | 104 | Search FORMULATION | Search FORMULATION |
9 | PROTEIN FOLDING REFOLDING | 116680 | 1% | 48% | 10 | Search PROTEIN+FOLDING+REFOLDING | Search PROTEIN+FOLDING+REFOLDING |
10 | PHYSICAL STABILITY | 103299 | 4% | 9% | 45 | Search PHYSICAL+STABILITY | Search PHYSICAL+STABILITY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | FUNKE, S , MATILAINEN, J , NALENZ, H , BECHTOLD-PETERS, K , MAHLER, HC , FRIESS, W , (2016) SILICONE MIGRATION FROM BAKED-ON SILICONE LAYERS. PARTICLE CHARACTERIZATION IN PLACEBO AND PROTEIN SOLUTIONS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 105. ISSUE 12. P. 3520 -3531 | 62 | 84% | 0 |
2 | CHAUDHURI, R , CHENG, Y , MIDDAUGH, CR , VOLKIN, DB , (2014) HIGH-THROUGHPUT BIOPHYSICAL ANALYSIS OF PROTEIN THERAPEUTICS TO EXAMINE INTERRELATIONSHIPS BETWEEN AGGREGATE FORMATION AND CONFORMATIONAL STABILITY.AAPS JOURNAL. VOL. 16. ISSUE 1. P. 48-64 | 62 | 70% | 16 |
3 | BRADER, ML , ESTEY, T , BAI, SJ , ALSTON, RW , LUCAS, KK , LANTZ, S , LANDSMAN, P , MALONEY, KM , (2015) EXAMINATION OF THERMAL UNFOLDING AND AGGREGATION PROFILES OF A SERIES OF DEVELOPABLE THERAPEUTIC MONOCLONAL ANTIBODIES.MOLECULAR PHARMACEUTICS. VOL. 12. ISSUE 4. P. 1005 -1017 | 44 | 76% | 10 |
4 | SAMRA, HS , HE, F , (2012) ADVANCEMENTS IN HIGH THROUGHPUT BIOPHYSICAL TECHNOLOGIES: APPLICATIONS FOR CHARACTERIZATION AND SCREENING DURING EARLY FORMULATION DEVELOPMENT OF MONOCLONAL ANTIBODIES.MOLECULAR PHARMACEUTICS. VOL. 9. ISSUE 4. P. 696-707 | 60 | 64% | 21 |
5 | TELIKEPALLI, SN , KUMRU, OS , KALONIA, C , ESFANDIARY, R , JOSHI, SB , MIDDAUGH, CR , VOLKIN, DB , (2014) STRUCTURAL CHARACTERIZATION OF IGG1 MAB AGGREGATES AND PARTICLES GENERATED UNDER VARIOUS STRESS CONDITIONS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 103. ISSUE 3. P. 796 -809 | 45 | 79% | 14 |
6 | GENG, SB , CHEUNG, JK , NARASIMHAN, C , SHAMEEM, M , TESSIER, PM , (2014) IMPROVING MONOCLONAL ANTIBODY SELECTION AND ENGINEERING USING MEASUREMENTS OF COLLOIDAL PROTEIN INTERACTIONS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 103. ISSUE 11. P. 3356 -3363 | 52 | 70% | 10 |
7 | MOUSSA, EM , PANCHAL, JP , MOORTHY, BS , BLUM, JS , JOUBERT, MK , NARHI, LO , TOPP, EM , (2016) IMMUNOGENICITY OF THERAPEUTIC PROTEIN AGGREGATES.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 105. ISSUE 2. P. 417 -430 | 48 | 57% | 5 |
8 | AMIN, S , BARNETT, GV , PATHAK, JA , ROBERTS, CJ , SARANGAPANI, PS , (2014) PROTEIN AGGREGATION, PARTICLE FORMATION, CHARACTERIZATION & RHEOLOGY.CURRENT OPINION IN COLLOID & INTERFACE SCIENCE. VOL. 19. ISSUE 5. P. 438 -449 | 54 | 59% | 22 |
9 | HAWE, A , WIGGENHORN, M , VAN DE WEERT, M , GARBE, JHO , MAHLER, HC , JISKOOT, W , (2012) FORCED DEGRADATION OF THERAPEUTIC PROTEINS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 101. ISSUE 3. P. 895 -913 | 67 | 49% | 49 |
10 | KALONIA, C , KUMRU, OS , KIM, JH , MIDDAUGH, CR , VOLKIN, DB , (2013) RADAR CHART ARRAY ANALYSIS TO VISUALIZE EFFECTS OF FORMULATION VARIABLES ON IGG1 PARTICLE FORMATION AS MEASURED BY MULTIPLE ANALYTICAL TECHNIQUES.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 102. ISSUE 12. P. 4256-4267 | 41 | 89% | 8 |
Classes with closest relation at Level 1 |